ArticleJournal of breast cancer2015
Breast Cancer Subtype as a Predictor of Lymph Node Metastasis according to the SEER Registry.
Article in Journal of breast cancer, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 32 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
32 citing papers in PubMed, 50 citations in OpenAlex.
- Nomogram-based estimate of axillary nodal involvement in ACOSOG Z0011 (Alliance): validation and association with radiation protocol variations.Breast cancer research and treatment · 2020Trial
- Trial
- Metastatic presentation of breast cancer in India: evidence from national cancer registry (2009-2020).The Lancet regional health. Southeast Asia · 2026Article
- An investigation to identify the factors for negative sentinel lymph node metastasis in early breast cancer cases.Breast cancer (Tokyo, Japan) · 2026Article
- Nomogram models for prediction of axillary lymph node metastasis in breast cancer patients.BMC cancer · 2025Article
- Sustainability in radiation oncology: opportunities for enhancing patient care and reducing COStrahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et al] · 2025Article
- Applying a multi-task and multi-instance framework to predict axillary lymph node metastases in breast cancer.NPJ precision oncology · 2025Article
- Preoperative ultrasonography-guided core-needle biopsy-based factors for predicting the upgrade of axillary lymph nodes in breast cancer.Quantitative imaging in medicine and surgery · 2025Article
- Retrospective comprehensive analysis of regional lymph node recurrence in breast cancer patients (REASON study).Journal of cancer research and clinical oncology · 2025Article
- Altered immune signatures in breast cancer lymph nodes with metastases revealed by spatial proteome analyses.Journal of translational medicine · 2025Article
- Predicting sentinel lymph node metastasis in breast cancer: a study based on the SEER database.Clinical and experimental medicine · 2025Article
- A preoperative prediction model for ipsilateral axillary lymph node metastasis of breast cancer based on clinicopathological and ultrasonography features: a prospective cohort study.Frontiers in oncology · 2025Article
- A nomogram model for predicting the risk of axillary lymph node metastasis in patients with early breast cancer and cN0 status.Oncology letters · 2024Article
- Article
- Prognosis prediction and risk factors for triple-negative breast cancer patients with brain metastasis: A population-based study.Cancer medicine · 2023Article
- Subtype of breast cancer influences sentinel lymph node positivity.Archives of medical science : AMS · 2023Article
- In Silico Identification of Genes Associated with Breast Cancer Progression and Prognosis and Novel Therapeutic Targets.Biomedicines · 2022Article
- Ultrasonography and clinicopathological features of breast cancer in predicting axillary lymph node metastases.BMC cancer · 2022Article
- Survival of BRCA1/BRCA2-associated pT1 breast cancer patients, a cohort study.Breast cancer research and treatment · 2022Article
- Age-Dependent Heterogeneity of Lymph Node Metastases and Survival Identified by Analysis of a National Breast Cancer Registry.Journal of pharmacy and pharmacology research · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeBreast cancer subtype correlates with response to systemic therapy and overall survival (OS), but its impact on lymphatic spread is incompletely understood. In this study, we used the Surveillance, Epidemiology, and End Results registry to assess whether the subtype can predict the presence of nodal metastasis or advanced nodal stage in breast cancer.
methodsA total of 7,274 eligible patients diagnosed with T1-3 infiltrating ductal carcinoma with known estrogen or progesterone hormone receptor (HR) and human epidermal growth factor receptor 2 (HER2) status, who underwent surgical excision of the primary tumor and pathologic lymph node evaluation, were included in this analysis. Patients were categorized into four breast cancer subtypes: HR+/HER2-; HR+/HER2+; HR-/HER2+; and HR-/HER2-. Binary logistic regression analysis was used to determine whether breast cancer subtype, tumor size, tumor grade, patient race, and patient age at diagnosis are independently predictive of lymph node positivity or advanced nodal stage. The Pearson chi-square test was used to determine whether progesterone receptor (PR) status had an impact on the incidence of lymph node positivity in estrogen receptor (ER) positive patients.
resultsIndependent predictors of nodal positivity included breast cancer subtype (p=0.040), tumor size (p<0.001), tumor grade (p<0.001), and patient age (p<0.001), whereas only tumor size (p<0.001), grade (p=0.001), and patient age (p=0.005) predicted advanced nodal stage. Triple-negative cancers had a significantly lower risk of nodal positivity than the HR+/HER2- subtype (odds ratio, 0.686; p=0.004), but no other significant differences between subtypes were observed. There was also no difference in lymph node positivity between PR+ and PR- tumors amongst ER+/HER2- (p=0.228) or ER+/HER2+ tumors (p=0.713).
conclusionThe HR+/HER2-breast cancer subtype has a higher rate of lymph node involvement at diagnosis than the triple-negative subtype. These findings may play a role in guiding regional management considerations if confirmed in further studies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.